Induction of Labor

CHAPTER 163 Induction of Labor



Although labor usually begins spontaneously, the induction of labor is one of the most common procedures in obstetrics. It is indicated for both maternal and fetal reasons as well as for elective and social reasons. The frequency at which patients undergo induction of labor has risen from 9% in 1989 to over 20% today. To induce labor, it may also be necessary to manipulate the cervical connective tissue. Therefore, induction can be viewed in two phases, cervical ripening followed by induction of contractions by artificial stimulation of the uterus.


The status of the cervix plays a vital role in the success or failure of an induction. The Bishop Scoring System is a tool that has been used for many years to help quantify the readiness of the cervix for labor (Table 163-1). The maximum score is 13. When the score exceeds 8, the likelihood of a successful vaginal delivery with use of oxytocin approaches that of spontaneous labor. A Bishop score of less than 6 correlates with a prolonged labor or failed induction. For research purposes, there is slight variation in the definition of an unfavorable cervix, with a Bishop score ranging from 4 to 6.



When a cervix is assessed as not favorable, ripening methods should be considered. Historically, nonpharmacologic methods such as breast stimulation, acupuncture, stripping (sweeping) of membranes, and placement of a Foley catheter or laminaria in the cervical os have been used. With the development of artificial prostaglandins (dinoprostone [prostaglandin E2; PGE2] and misoprostol [PGE1]), use of pharmacologic methods has surpassed these other methods. If a cervix is favorable or ripening techniques have been used, it is reasonable to use oxytocin or amniotomy (see Chapter 164, Amniotomy) to stimulate the uterus to have regular and rhythmic contractions.


Providers and nursing staff should develop protocols, as a team, for management of labor induction, including possible complications. These policies should be in written form and followed to maximize safety for the mother and infant and to reduce liability for the providers and institution. Protocols should outline not only the procedural technique but the indications and contraindications. Special attention should be given to the protocols for elective inductions and for induction in women with a previous cesarean section.






Equipment and Supplies








NOTE: Dinoprostone should be stored between −20° C and −10° C. Because misoprostol is available only in a 100-µg dosage, it is recommended to have the pharmacist cut the tablet into quarters to ensure the correct dose.


EDITOR’S NOTE: A meta-analysis of randomized, controlled trials comparing dinoprostone with misoprostol for cervical ripening and induction of labor found the time to delivery was shorter and the rate of cesarean delivery was lower in the misoprostol group.









Preprocedure Patient Education and Forms


All patients should be counseled regarding the indications for induction, the expected results, the alternatives, and the possible adverse effects, including the increased risks for cesarean section, uterine hyperstimulation, and fetal distress. The U.S. Food and Drug Administration (FDA) has approved only oxytocin and dinoprostone for labor induction. Review the possible complications with the patient (and family, if present). The clinician should be familiar with the package insert information. With use of prostaglandins, vomiting, diarrhea, or fever may occur, but a recent review of the literature indicated no difference between treatment and control for use of prostaglandins for cervical ripening. Laminaria are made from brown seaweed and act by drawing water from the cervix and swelling, which softens and then dilates the cervix. If a laminaria is inserted, some clinicians will let the patient go home; however, there is a slight increased risk of infection. Anaphylaxis has also been reported. With either laminaria or Foley catheter, the patient will typically experience cramping as the cervix dilates.


Misoprostol is not approved by the FDA for this use. There is a “black box warning” against the use of misoprostol during pregnancy. Patients should be informed of the off-label use and possible complications of any prostaglandin, as listed later. It may be helpful to remind the patient that clinicians frequently use medications off-label (e.g., most of the common medications used to halt preterm labor are off-label). Furthermore, misoprostol is contraindicated in patients who have had a previous cesarean delivery.

Stay updated, free articles. Join our Telegram channel

May 14, 2017 | Posted by in GENERAL & FAMILY MEDICINE | Comments Off on Induction of Labor

Full access? Get Clinical Tree

Get Clinical Tree app for offline access